• Login
View Item 
  • DASH Home
  • Faculty of Arts and Sciences
  • FAS Scholarly Articles
  • View Item
  • DASH Home
  • Faculty of Arts and Sciences
  • FAS Scholarly Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of DASH
  • Communities & Collections
  • By Issue Date
  • Author
  • Title
  • Keyword
  • FAS Department
This Collection
  • By Issue Date
  • Author
  • Title
  • Keyword
  • FAS Department

Submitters

  • Login
  • Quick submit
  • Waiver Generator

About

  • About DASH
  • DASH Stories
  • DASH FAQs
  • Accessibility
  • COVID-related Research
  • Terms of Use
  • Privacy Policy

Statistics

  • By Schools
  • By Collections
  • By Departments
  • By Items
  • By Country
  • By Authors

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

 
Thumbnail
View/Open
3892920.pdf (549.3Kb)
Author
Tomasetti, Cristian
Demetri, George DHARVARD
Parmigiani, GiovanniHARVARD
Published Version
https://doi.org/10.12688/f1000research.2-152.v1
Metadata
Show full item record
Citation
Tomasetti, Cristian, George D Demetri, and Giovanni Parmigiani. 2013. “Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.” F1000Research 2 (1): 152. doi:10.12688/f1000research.2-152.v1. http://dx.doi.org/10.12688/f1000research.2-152.v1.
Abstract
Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. Methods and results: By combining clinical and experimental observations with mathematical formulas we estimate that, in advanced GIST, the genetic changes responsible for resistance are generally already present at disease detection. Conclusion: This result has relevant clinical implications by providing support for the exploration of combination therapies.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892920/pdf/
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879540

Collections
  • FAS Scholarly Articles [17582]
  • HMS Scholarly Articles [17730]
  • SPH Scholarly Articles [6387]

Contact administrator regarding this item (to report mistakes or request changes)

Follow us on TwitterFollow us on FacebookFollow us on Google+

e: osc@harvard.edu

t: +1 (617) 495 4089

f: +1 (617) 495 0370

© 2018 President and Fellows of Harvard College
  • DASH
  • ETDs@Harvard
  • Copyright First Responders
  • HOPE
  • Contact
  • Harvard Library
  • Harvard University